Department of Surgery, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China.
J Gastrointest Surg. 2018 Nov;22(11):1928-1938. doi: 10.1007/s11605-018-3840-8. Epub 2018 Jun 29.
The aim of this study was to examine the merits of the anterior approach, if any, in colorectal liver metastasis (CRLM) resection.
Data of patients who underwent partial hepatectomy for CRLM were reviewed. Patients treated by the anterior approach were compared with patients treated by the conventional approach.
Ninety-eight patients had right hepatectomy, extended right hepatectomy, or right trisectionectomy. Among them, 71 patients underwent the conventional approach (CA group) and 27 underwent the anterior approach (AA group). The two groups were comparable in demographic, pathological, and perioperative characteristics except that the AA group had higher levels of aspartate transaminase (median, 41 vs. 31 U/L; p = 0.006) and alanine transaminase (median, 27 vs. 22 U/L; p = 0.009), larger tumors (median, 7 vs. 4 cm; p = 0.000), and more extensive resections (p < 0.001). The median overall survival was 40 months (range, 0.69-168.6 months) in the CA group and 33.7 months (range, 0.95-99.8 months) in the AA group (p = 0.22), and the median disease-free survival was 9.7 months (range, 0.62-168.6 months) in the CA group and 6.2 months (range, 0.72-99.8 months) in the AA group (p = 0.464). Univariate and multivariate analyses identified 4 independent prognostic factors for overall survival: lymph node status of primary tumor (HR 1.352, 95% CI 0.639-2.862, p = 0.034), intraoperative blood loss (HR 1.253, 95% CI 1.039-1.510, p = 0.018), multiple liver tumor nodules (HR 1.775, 95% CI 1.029-3.061, p = 0.039), and microvascular invasion (HR 2.058, 95% CI 1.053-4.024, p = 0.035).
The two approaches resulted in comparable survival outcomes even though the AA group had larger tumors and more extensive resections. The anterior approach allows better mobilization and easier removal of large tumors once the liver is opened up.
本研究旨在探讨前入路在结直肠癌肝转移(CRLM)切除中的优势。
回顾接受部分肝切除术治疗 CRLM 的患者数据。比较采用前入路治疗的患者和采用常规入路治疗的患者。
98 例患者行右半肝切除术、扩大右半肝切除术或右三叶切除术。其中,71 例患者接受常规入路(CA 组),27 例患者接受前入路(AA 组)。两组在人口统计学、病理学和围手术期特征方面无差异,除 AA 组天门冬氨酸转氨酶(中位值,41 比 31 U/L;p = 0.006)和丙氨酸转氨酶(中位值,27 比 22 U/L;p = 0.009)水平更高、肿瘤更大(中位值,7 比 4 cm;p = 0.000)、切除范围更广(p < 0.001)外。CA 组中位总生存期为 40 个月(范围,0.69-168.6 个月),AA 组为 33.7 个月(范围,0.95-99.8 个月)(p = 0.22),CA 组无病生存期为 9.7 个月(范围,0.62-168.6 个月),AA 组为 6.2 个月(范围,0.72-99.8 个月)(p = 0.464)。单因素和多因素分析确定了总生存的 4 个独立预后因素:原发肿瘤淋巴结状态(HR 1.352,95%CI 0.639-2.862,p = 0.034)、术中出血量(HR 1.253,95%CI 1.039-1.510,p = 0.018)、多个肝肿瘤结节(HR 1.775,95%CI 1.029-3.061,p = 0.039)和微血管侵犯(HR 2.058,95%CI 1.053-4.024,p = 0.035)。
尽管 AA 组肿瘤较大,切除范围较广,但两种方法的生存结果相当。一旦打开肝脏,前入路允许更好地移动和更容易地切除大肿瘤。